Skip to main content

Outlook Therapeutics, Inc. (OTLK)

NASDAQ: OTLK · Delayed Price · USD
2.12
-0.02 (-0.94%)
After-hours:Oct 20, 2021 5:20 PM EDT
2.14
0.03 (1.42%)
At close: Oct 20, 4:00 PM

Income Statement (Annual)

Financials in millions USD. Fiscal year is October - September.
Year2020201920182017201620152014
Revenue
08.153.093.812.985.229.05
Revenue Growth
-163.84%-18.99%27.92%-42.91%-42.33%-
Gross Profit
08.153.093.812.985.229.05
Selling, General & Admin
9.979.3714.2315.8821.5612.917.32
Research & Development
26.3423.8118.523.8132.7638.8814.12
Other Operating Expenses
0.5311.2700000
Operating Expenses
36.8444.4532.7339.6954.3351.7821.44
Operating Income
-36.84-36.3-29.64-35.88-51.35-46.56-12.39
Interest Expense / Income
1.763.473.895.631.852.30.9
Other Expense / Income
-0.09-1.830.2-3.160-1.280
Pretax Income
-38.51-37.93-33.74-38.35-53.2-47.58-13.29
Income Tax
-3.27-3.41-3.650.50.1-0.190.44
Net Income
-35.24-34.52-30.09-38.85-53.3-47.39-13.73
Preferred Dividends
13.631.5217.931.189.845.616.93
Net Income Common
-48.87-36.04-48.02-40.03-63.14-53-20.66
Shares Outstanding (Basic)
731853211
Shares Outstanding (Diluted)
731853211
Shares Change
298.84%268.84%64.12%39.67%76.48%14.62%-
EPS (Basic)
-0.67-1.98-9.74-13.36-29.36-43.44-19.44
EPS (Diluted)
-0.67-1.98-9.74-14.40-29.36-43.44-19.44
Free Cash Flow Per Share
-0.44-1.80-7.26-5.26-21.65-29.76-8.82
Gross Margin
-100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
--445.60%-960.12%-941.36%-1723.30%-892.13%-136.92%
Profit Margin
--423.81%-974.62%-1019.26%-1788.91%-908.05%-151.73%
Free Cash Flow Margin
--401.75%-1160.16%-414.46%-1563.34%-695.13%-103.72%
Effective Tax Rate
8.50%8.99%10.81%-1.31%-0.19%0.40%-3.30%
EBITDA
-36.2-31.11-26.79-30.03-48.95-43.46-11.51
EBITDA Margin
--381.85%-867.82%-787.87%-1642.95%-832.72%-127.22%
EBIT
-36.75-34.47-29.85-32.72-51.35-45.29-12.39
EBIT Margin
--423.12%-966.75%-858.50%-1723.30%-867.68%-136.92%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).